Loading patent…
AssigneesSterrenbeld Biotechnologie North America, Inc., Fundacion Universitaria Dr. Rene G. Favaloro
InventorsRubén Laguens, Marcelo L. Arguelles, Gustavo Leónidas Vera Janavel, José Alberto Crottogini, Carlos Alberto Melo, Ricardo Horacio Pichel, Marcelo Eduardo Criscuolo
Estimating the term…
The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotide) is administered into the myocardium.
A method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis in a cell or tissue in need thereof, comprising administering directly to the cell or tissue a dose of a polynucleotide that encodes the vascular endothelial growth factor, VEGF 1-165, or that encodes a polypeptide comprising an active variant of the VEGF 1-165, wherein the coding sequence is operably linked to a CMV promoter and is in a plasmid vector, the dose being in a sufficient amount to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis.
A method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis in a subject in need of such treatment, comprising administering to the subject a dose of a VEGF 1-165 polypeptide, or of an active variant thereof, which is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis.
Dependencies are inferred from the claim text.